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We have developed a robust in vivo small-molecule
screen that modulates heart size and cardiomyocyte
generation in zebrafish. Three structurally related
compounds (Cardionogen-1 to Cardionogen-3) iden-
tified from our screen enlarge the size of the devel-
oping heart via myocardial hyperplasia. Increased
cardiomyocyte number in Cardionogen-treated em-
bryos is due to expansion of cardiac progenitor
cells. In zebrafish embryos and murine embryonic
stem (ES) cells, Cardionogen treatment promotes
cardiogenesis during and after gastrulation, whereas
it inhibits heart formation before gastrulation.
Cardionogen-induced effects can be antagonized
by increasing Wnt/b-catenin signaling activity.
We demonstrate that Cardionogen inhibits Wnt/
b-catenin-dependent transcription in murine ES cells
and zebrafish embryos. Cardionogen can rescue
Wnt8-induced cardiomyocyte deficiency and heart-
specificphenotypesduringdevelopment. Thesefind-
ings demonstrate that in vivo small-molecule screens
targetingheart size can reveal compoundswith cardi-
omyogenic effects and identify underlying target
pathways.
INTRODUCTION
Dysregulation of heart development and growth is a hallmark of
most cardiovascular diseases (Olson, 2004). Screening for small
molecules that regulate cardiomyocyte generation will further
our understanding of cardiac developmental mechanisms and
aid in discovering novel therapeutics for heart diseases. The
zebrafish has emerged as a model organism used in multiple
steps of the drug discovery process through their use in in vivo
phenotypic screens (Leha´r et al., 2008; Murphey and Zon,1658 Chemistry & Biology 18, 1658–1668, December 23, 2011 ª20112006). Whole-embryo screens offer considerable advantages
in drug discovery by evaluating target cell populations and
organs, as well as other pleiotropic effects. Established heart-
specific zebrafish transgenic lines permit visualization of green
fluorescent proteins in developing hearts. These features make
zebrafish particularly well suited for discovering small-molecule
regulators of cardiac development and growth.
Despite advances in modern medicine, management of
myocardial infarction and heart failure remains a major chal-
lenge. Developing therapies that can stimulate cardiomyocyte
regeneration in areas of infarction would have an enormous
medical and economic impact. Both embryonic and adult stem
cells have received considerable attention as donor cells for
therapeutic applications. Use of pluripotent embryonic stem
(ES) cells is largely limited by ethical issues and concerns of their
tumorigenic potential (Behfar et al., 2002), whereas recent trials
featuring adult donor stem cells have demonstrated only modest
clinical benefits (Lunde et al., 2006; Scha¨chinger et al., 2006).
These findings demonstrate a limited capacity of donor stem
cells to differentiate into cardiomyocytes, and they highlight
the need to develop small molecules that induce differentiation
of exogenous and endogenous stem cells toward cardiac cell
lineages.
Zebrafish cardiac development begins during the early stages
of embryogenesis. Generation of the required number of cardio-
myocytes involves both production of cardiac progenitor cells
and proliferation of embryonic cardiomyocytes (Stainier, 2001).
The size of the embryonic heart primarily reflects cardiac
cell number and cell size (Jia et al., 2007). Several signaling
pathways, including bone morphogenic protein (BMP), Wnt,
fibroblast growth factor (FGF), Notch, and retinoic acid, are
implicated in the initial selection of myocardial progenitors
from a multipotential stem cell population (Keegan et al., 2005;
Marques et al., 2008; Reiter et al., 2001; Rones et al., 2000).
Among this population, the Wnt signaling pathway has received
considerable attention for its roles in development, stem cell
formation, regeneration, and cancer progression(Logan and
Nusse, 2004; Moon et al., 2004). Canonical Wnt signaling is
mediated by binding of secreted (Wnt) proteins to specificElsevier Ltd All rights reserved
A B Figure 1. In Vivo Small Molecule ScreenIdentified Bioactive Compounds that Affect
Heart Development
(A) Schematic diagram displaying the screening
process for compounds that affect heart devel-
opment. Three Tg(cmlc2-EGFP) embryos were
transferred to each well in E3 buffer at the con-
centration of test compounds to 10 mM.
(B) Log P values (partition coefficients between
octanol and water) of all active compounds iden-
tified in the screen plotted against their respec-
tive molecular weights. The bioactive compounds
have molecular weights ranging from 200 to 500
Daltons and log P values ranging from 1 to +7.
Positive log P value = hydrophobic. Negative log P
value = hydrophilic. Bioactive compounds were
subclassified by cardiac phenotypes observed
with treatment (10 mM).
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Discovery of Cardiogenic Small MoleculesFrizzled receptor complexes, and this results in inactivation of
GSK-3b, leading to dephosphorylation and stabilization of cyto-
plasmic b-catenin. b-catenin then translocates into the nucleus
and activates T cell factor (Tcf)/lymphoid-enhancing-factor
(Lef)-mediated transcription (Logan and Nusse, 2004; Moon
et al., 2004). During zebrafish heart development, Wnt/b-catenin
signaling regulates heart development in a temporally biphasic
fashion. It induces cardiac specification before gastrulation but
inhibits heart formation during and after gastrulation (Ueno
et al., 2007). Although core components of the Wnt signaling
pathway are clearly defined and highly conserved, tissue-
specific modifiers of the pathway remain a mystery (Logan and
Nusse, 2004; Moon et al., 2004).
In this study, we screened a small-molecule library for com-
pounds using an in vivo cardiac development assay. A novel
small-molecule family containing three structurally related com-
pounds (Cardionogen-1, -2, and -3) was identified based on the
ability of its compounds to selectively enlarge the size of the
embryonic heart.We show that Cardionogen is a biphasicmodu-
lator of cardiogenesis, either promoting or inhibiting heart for-
mation, depending on the stage of treatment. Cardionogen
treatment also promotes murine ES cells to differentiate into
beating cardiomyocytes, demonstrating that the bioactivity of
this small-molecule family is functionally conserved in mamma-
lian cells. We indicate that Cardionogen inhibits Wnt/b-catenin-
dependent transcriptional activity in murine ES cells (EC50 of
23 nM) and zebrafish embryos. Furthermore, Cardionogen
can rescue cardiac cell and chamber deficiency induced by
Wnt8 after gastrulation and reverse cardiac cell expansion
caused by Wnt8 overexpression before gastrulation. These find-
ings indicate that Cardionogen interferes with Wnt signaling
during cardiac development and growth.
RESULTS
In Vivo Chemical Screens for Small-Molecule
Modulators of Heart Development
The size of the zebrafish embryonic heart primarily reflects the
number and size of cardiomyocytes during development (Jia
et al., 2007). We hypothesized that screening for small molecules
that increase heart size in zebrafish embryos may identifyChemistry & Biology 18, 1658–166compounds that induce cardiomyocyte differentiation and pro-
liferation without causing pleiotropic effects. To test this hypoth-
esis, we conducted an in vivo cardiac development screen using
transgenic zebrafish embryos (Tg[cmlc2:EGFP]) in which ex-
pression of enhanced green fluorescent protein (EGFP) is under
the control of the cardiac myosin light chain 2 (cmlc2) promoter
(Burns et al., 2005). The primary focus of our screen was heart
size, which was assessed by visual inspection using fluores-
cent microscopy. We adopted and modified a small-molecule
screening procedure using zebrafish embryos (Peterson et al.,
2004; Stern et al., 2005). Briefly, aliquots of test compounds
were delivered into individual wells of 96-well tissue-culture
plates (Figure 1A). cmlc2-EGFP transgenic embryos were har-
vested from crosses of transgenic fish and added to test wells
at 5 hr postfertilization (hpf), the onset of gastrulation when
cardiac progenitor cells begin to form (Stainier, 2001). We exam-
ined embryonic heart size, cardiac morphology, and contractility
of treated embryos at 24, 48, and 72 hpf. In addition, overall
morphologies of embryos (e.g., dorsal-ventral and anterior-
posterior axes) and other organs, including the brain, eyes, noto-
chord, and somites, were carefully examined to determine
whether development of these organs was affected, providing
a preliminary assessment of compound selectivity and toxicity.
A subset of the small-molecule library (4,000 compounds with
diverse structures) provided by the Vanderbilt Institute of Chem-
ical Biologywas screened. Sixty-one compoundswere identified
as having significant effects on heart size, morphology, and
contractility. Of these compounds, 15 caused an enlarged heart
phenotype, 17 induced ectopic EGFP expression, 13 caused
arrhythmias, and 16 delayed development at the heart tube
stage. Notably, almost all bioactive compounds were hydro-
phobic, as indicated by positive log P values (the partition coef-
ficient between octanol and water), suggesting that hydrophobic
compounds effectively penetrate zebrafish embryos (Figure 1B).
This observation is consistent with the results of previous
small-molecule screens in zebrafish (Sachidanandan et al.,
2008). vuc230, vuc198, and vuc247, named as Cardionogen
(CDNG)-1, -2 and -3, were among the most potent inducers
of a large-heart phenotype identified in our screen. Notably,
these small molecules are structurally related and contain
the same core motif, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1659
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A Figure 2. Cardionogen Increases Heart Size during
Zebrafish Development
(A) Chemical structures of the Cardionogen family,
including CDNG1/vuc230, CDNG2/vuc198, and CDNG3/
vuc247.
(B–F) Fluorescent optics displaying untreated control heart
(CTL) (B), CDNG1-treated heart (C), CDNG2-treated heart
(D), untreated control embryo (CTL) (E), and CDNG1-
treated embryo (F) in Tg[cmlc2:EGFP] embryos at 60 hpf.
(G and H) Light optics showing control embryos (CTL) (G)
and CDNG1-treated embryos (H) at 60 hpf.
(B–D) Ventral view; (E–H) lateral view. Red arrow, ventricle;
blue arrow, atrium. CDNG1 treatment (30 mM, 5 to 60 hpf).
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Discovery of Cardiogenic Small Molecules(Figure 2A). Treatment with Cardionogen-1/vuc230 (IUPAC:
6-cyclohexyl-3-furan-2-yl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole)
or Cardionogen-2/vuc198 (IUPAC: 6-(3,4-dimethoxyphenyl)-3-
pyridin-2-yl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole) significantly
enlargedboth theatriumandventricle (Figures2B–2D).Cardiono-
gen-3/vuc247 (IUPAC: 3-pyridin-4-yl-6-(thiophen-2-ylmethyl)-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole) affected heart size to a
lesser extent than Cardionogen-1 and -2 (data not shown). Car-
dionogen treatment did not cause apparent defects of overall
embryonic morphology or other organ development (Figures
2E–2H), suggesting that this class of small molecules has selec-
tive activity on heart development and growth.
Cardionogen Induces Cardiac Hyperplasia in a Biphasic
Manner
To assess whether heart enlargement is due to hyperplastic
and/or hypertrophic growth, we evaluated cardiac cell num-
ber, cell size, and proliferative rates after treatment with both
Cardionogen-1 and -2. We quantified total cardiomyocyte num-
ber in Tg(cmlc2:DsRed-nuc) embryos in which a gene encoding
red fluorescent protein fused to a nuclear localization signal
(DsRed-nuc) is under the control of the cmlc2 promoter (Mably
et al., 2003). In these transgenic embryos, individual cardiomyo-
cyte nuclei are marked by red fluorescence, permitting quanti-
tative assessment of cardiomyocyte number using confocal
microscopy analysis (FigureS1A). To this end,wecomparedCar-
dionogen-treated embryos versus controls in a series of flat-
mount confocal sections. Cardionogen treatment caused an
increase of cardiac cell numbers in both the atrium and ventricle
(Figure 3A). To test whether hypertrophy of cardiomyocytes also
contributed to increases in heart size, we measured cell size in
Tg(cmlc2:EGFP) embryos using confocal microscopy. No alter-1660 Chemistry & Biology 18, 1658–1668, December 23, 2011 ª2011 Elsevier Ltd All rations in cell size were observed with Cardio-
nogen treatment (Figure S1B). Whole-mount
immunohistochemistry assays (n = 10 embryos)
using antibodies that recognize the mitosis
marker phosphohistone 3 (H3P) revealed that
cardiomyocyte proliferation was not increased
in Cardionogen-1-treated embryos in compar-
ison to control embryos (data not shown).
Dosage-response analyses revealed that Car-
dionogen exponentially reached its optimum
activity at 40 mMandmaintained its peak activity
at higher concentration ranges (Figure 3B). No
differences in survivorship or general mor-phology were noted at any of the test concentrations. Taken
together, our results indicate that Cardionogen enlarges heart
size via cardiac hyperplasia, which is not attributed to increases
in the proliferative growth of cardiomyocytes.
The results presented above suggest that Cardionogen may
affect earlier stages of cardiac cell differentiation. To assess
the temporal activity of Cardionogen, we quantified cardiomyo-
cyte number in transgenic embryos (Tg[cmlc2:DsRed-nuc]) after
pulse treatments with Cardionogen-1. In the first set of pulse
experiments, Cardionogen-1 was added at 2 hpf (the beginning
of blastula) and washed away at progressively later stages of
development, including 5 hpf (the onset of gastrula) and 12 hpf
(the 5-somite stage), when nkx2.5 starts to express (Figure 3C).
Cardiac cell counts were conducted at 60 hpf. Cardionogen
treatment had an inhibitory effect on cardiomyocyte generation
with treatment from 2 hpf to 5 hpf (178 ± 3) in comparison with
controls (212 ± 5) (Figure 3D). Extension of Cardionogen treat-
ment to 12 hpf recovered the loss of cells (219 ± 4) (Figures 3C
and 3D). In a second set of pulse experiments, Cardionogen-1
was added at 5 hpf and washed away at 12 hpf or 60 hpf (Fig-
ure 3C). We quantified cell number at 60 hpf and observed
increased cardiac cell numbers with treatment from 5 hpf to 12
hpf (245 ± 5) and from 5 hpf to 60 hpf (305 ± 4), compared to
controls (212 ± 5) (Figure 3D). In embryos treated from 12 hpf
to 60 hpf, cardiomyocyte number was reduced from the
peak but still showed a marked increase compared to controls
(265 ± 5 versus 212 ± 5) (Figures 3C and 3D). Together, these
results suggest that Cardionogen has a temporally biphasic
pattern of cardiomyogenic activity during development. Specifi-
cally, Cardionogen treatment promotes cardiogenesis during
and after gastrulation, whereas treatment before gastrulation
inhibits cardiomyocyte formation.ights reserved
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Figure 3. Cardionogen Induces Cardiac
Hyperplasia in a Biphasic Manner
(A) Bar chart showing increased cardiac cell
number in the atrium and ventricle in CDNG1- and
CDNG2-treated embryos at 30 mM (5–60 hpf).
(B) Dose-response curve for heart enlargement
with CDNG1 treatment. Tg(cmlc2:EGFP) (n = 30)
embryos were treated at 5 hpf using CDNG1
compound at various concentrations (0–100 mM).
Heart sizes were scored at 60 hpf. No differences
in survivorship or general morphology were noted
at any of the test concentrations.
(C) Schematic representation showing pulse
treatment intervals used to define Cardionogen
bioactivity period in cardiomyogenesis.
(D) Graph showing cardiomyocyte number in
embryos treated by CDNG1 pulse during different
stages. Three to five embryos were subjected
to confocal imaging under each condition with
CDNG1 treatment (30 mM), and cardiomyocyte
numbers were counted using confocal micros-
copy analysis. All cell countswere conducted at 60
hpf. Error bars indicate the standard deviation in
three independent measurements (A, B, and D).
Asterisks indicate statistical significance between
treated and control embryos (*p < 0.01) (A and D).
See also Figure S1.
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Cells
To understand howCardionogen treatment regulates cardiogen-
esis, we performed in situ hybridization analyses with the cardiac
progenitor marker nkx2.5 and cardiac differentiation markers
cmlc2 and ventricular myosin heavy chain (vmhc) (Yelon et al.,
1999). In Cardionogen-1-treated embryos, marked increases in
nkx2.5 expression were observed in the anterior lateral plate
mesoderm, the definitive heart field (the heart-forming region)
(Schoenebeck et al., 2007) at 12 hpf, as well as the heart tube
stage at 24 hpf (Figures 4A, 4B, 4G, and 4H). Cardiomyocyte
populations of Cardionogen-treated embryos were also ex-
panded at the onset of myocardial differentiation, as evidenced
by increased expression of cmlc2 and vmhc at 17 hpf (Figures
4C–4F). In contrast, expression of scl, a hematopoietic progen-
itor marker in the head and the lateral mesoderm, was not
affected in treated embryos compared to controls (Figures 4I
and 4J). Similarly, expression of insulin, a pancreas marker,
and myoD, a skeletal myoblast marker, did not appear to be
affected in Cardionogen-treated embryos (Figures 4K–4N).
These observations indicate that Cardionogen promotes cardiac
hyperplasia via expanding the cardiac progenitor cell population.
Cardionogen Promotes Mouse ES Cells to Differentiate
into Beating Cardiomyocytes
To examine Cardionogen activity in a mammalian model, we
employed a murine ES cell line (Tg[aMHC:DsRed-Nuc]) that
was stably transfectedwith aDsRed-Nuc construct driven by the
promoter of a-myosin heavy chain (aMHC) (Hao et al., 2008; Sub-
ramaniam et al., 1991). In this transgenic line, differentiating car-
diomyocytes are marked by prominent nuclear red fluorescence
(Hao et al., 2008). Embryoid bodies (EBs) were initiated (marked
as day 0) in cultured ES cells. Pulse treatment of Cardionogen-1
during the initial ES cell differentiation from day 0 to day 4 failedChemistry & Biology 18, 1658–166to induce cardiomyocyte differentiation when examined at day
12 (data not shown). Cardionogen-1 treatment from day 4 to
day 10 significantly promoted ES cell differentiation into cardio-
myocytes that express DsRed (Figures 5A–5D). We have found
that Cardionogen-1 at 1 mMand 5 mM, but not at 0.1 mM, induces
ES cell cardiac differentiation (Figures 5A–5D; data not shown).
This treatment period coincides with the late differentiation of
three germ layers in the EBs. Furthermore, cardiomyocytes gen-
erated from treated EBs formed foci that spontaneously and
rhythmically contracted (Movies S1 and S2 available online).
Finally, we determined the fraction of ES cell culture expressing
aMHC using flow cytometry. Cardionogen treatment from day 4
to day 10 increased the cardiac cell percentage 4.36-fold
(Figures 5E–5G). The overall cardiac differentiation percentages
are consistent with previous studies using Wnt3a or GSK3b
inhibitor BIO (Naito et al., 2006; Ueno et al., 2007).
To further assess the induction of cardiac cell differentiation,
we examined expression of cardiac differentiation markers
by real-time PCR. Treating ES cells from day 4 to day 10 with
Cardionogen-1 and -2 significantly increased expression of
cardiac sarcomere genes, including bMHC, aMHC, myosin light
chain-2a (MLC-2a), and MLC-2v (Figure 5H), whereas pulse
treatment of ES cells with Cardionogen from day 0 to day 4
downregulated expressions of these four cardiac markers in
RNA samples prepared at day 12 (Figure 5H). Furthermore, Car-
dionogen treatment of ES cells starting at day 4 induced the
expression of cardiac progenitor cell marker islet (Figure 5H).
Hence, Cardionogen treatment after the appearance of cells rep-
resenting the different germ layers promoted cardiomyocyte
differentiation, whereas treatment before this stage led to a
decrease in cardiogenesis. These studies reveal a biphasic
pattern of the cardiomyogenic activity of Cardionogen during
murine ES cell differentiation, and the results closelymimic those
obtained from our studies in zebrafish.8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1661
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Figure 4. Cardionogen Promotes Expan-
sion of the Cardiac Progenitor Cell Popula-
tion
Expression of nkx2.5 (A and B), cmlc2 (C and D),
vmhc (E and F), nkx2.5 (G and H), scl (I and J),
insulin (K and L), and myoD (M and N) in CDNG1-
treated and control embryos was examined using
in situ hybridization. Expression of nkx2.5 [39 of 43
embryos in (A) and (B)], cmlc2 [42 of 47 embryos in
(C) and (D)], vmhc [41 of 45 embryos in (E) and (F)],
and nkx2.5 [38 of 41 embryos in (G) and (H)] is
increased. Expression of scl (41 of 43 embryos),
insulin (42 of 45 embryos), and myoD (39 of 42
embryos) is not altered. Images were taken at
12 hpf (A, B, I, and J), 17 hpf (C–F), 24 hpf (G, H, M,
and N), and 48 hpf (K and L). Dorsal (A–F and I–L)
and lateral views (G, H, M, and N) are shown.
CTL, control; black arrow, heart tube. CDNG1,
30 mM.
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Transcription
Cardionogen promotes cardiomyocyte generation following
gastrulation and inhibits heart formation prior to gastrulation.
Inversely, Wnt/b-catenin signaling during and after gastrulation
inhibits cardiogenesis, whereas signaling before gastrulation
induces heart formation (Naito et al., 2006; Ueno et al., 2007).
These apparently opposing activities of Cardionogen and Wnt/
b-catenin signaling led us to hypothesize that Cardionogen
modulates heart development by antagonizing Wnt/b-catenin
activity. The canonical Wnt/b-catenin pathway is a highly con-
served signaling pathway whereby activation of Wnt signaling
causes b-catenin to translocate into the nucleus and bind to
Tcf and Lef transcription factors, resulting in activation of down-
stream gene expression (Logan and Nusse, 2004; Moon
et al., 2004). To determine whether Cardionogen opposes Wnt/
b-catenin activity, we performed b-catenin/Tcf-mediated tran-
scription assays. We employed a murine CGR8 embryonic
stem cell line that was stably transfected with a TOPflash con-
struct containing six copies of the Tcf/Lef binding site upstream
of the thymidine kinase minimal promoter and luciferase cDNA
(Ishitani et al., 1999). In this assay, Wnt3a was used to activate
TOPflash luciferase activity. Cardionogen-1 inhibited Wnt3a/
b-catenin-mediated luciferase activity in a dose-dependent
manner. Effector Cardionogen concentrations for half-maximal
response (EC50) and maximal response are 23 nM and 100 nM,
respectively (Figure 6A). IWR1, a known Wnt inhibitor (Chen
et al., 2009), reduced TOPflash activity, as a positive control (Fig-
ure 6A). In contrast, Cardionogen-1 failed to inhibit TOPflash
activity induced by DNLef-VP16 (Figure 6B). DNLef-VP16 can1662 Chemistry & Biology 18, 1658–1668, December 23, 2011 ª2011 Elsevier Ltd All rights reactivate TOPflash activity independently
of catenin, through a process in which
DNLef, lacking a b-catenin binding site,
fuses with transactivation domain VP16
(Aoki et al., 1999). As a control, IWR1
also failed to reduce DNLef-VP1-induced
TOPflash activity (Figure 6B). Together,
these findings suggest that Cardionogen
inhibits b-catenin-dependent Wnt sig-naling. We next examined whether Cardionogen disrupted
Wnt/b-catenin signaling within responding cells. LRP6ICD,
a Wnt coreceptor, can constitutively activate Wnt signaling
within cells (Tahinci et al., 2007; Tamai et al., 2004). GCR8-ES
cells were transfected with LRP6ICD. Cardionogen-1 treatment
resulted in a reduction of LRP6ICD-induced TOPflash activity,
whereas IWR1 caused loss of the same luciferase activity
(Figure 6C). Thus, Cardionogen blocks Wnt/b-catenin signaling
within responding cells rather than disrupting ligand-cell inter-
action or ligand production. Finally, we determined whether
Cardionogen treatment altered other signaling activities.
Cardionogen-1 did not reduce BMP4-induced Id2 expression,
whereas Dorsomorphin (DM), a known BMP4 inhibitor, did
reduce Id2 expression (Figure 6D). Furthermore, Cardionogen-1
failed to alter Notch- or SRF/MAPK-induced transcription in ES
cells (Figures S2A and S2B). These findings demonstrate the
Cardionogen specificity for Wnt signaling.
To test whether Cardionogen inihibits Wnt signaling in devel-
oping embryos, we examined the effects of Cardionogen on
GFP expression in Tg(TOP:GFP) embryos, in which GFP trans-
gene expression is under the control of four consensus Lef
binding sites and a minimal cFos promoter (Dorsky et al.,
2002). In Tg(TOP:GFP) embryos, GFP fluorescence is only
observed in the midbrain using fluorescent microscopy analysis
(Figures 6E and 6F) (Dorsky et al., 2002). We were unable to
observe GFP fluorescence in other embryo regions, which is
consistent with previous studies (Dorsky et al., 2002). Neverthe-
less, treating Tg(TOP:GFP) embryos with Cardionogen-1 re-
duced GFP fluorescence in the midbrain (Figures 6G and 6H).
As a control, IWR1 treatment caused loss of GFP fluorescenceserved
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Figure 5. Cardionogen Induces Murine ES Cells to Differentiate into Cardiomyocytes
(A and B) Fluorescent optics revealing myocardial differentiation (red areas) in 0.1% DMSO-treated (CTL) and 1 mM CDNG1-treated CGR8-ES cells
(Tg[aMHC:DsRed-nuc]).
(C and D) Bright-field pictures merged with fluorescent images of control (A) and CDNG1-treated cells (B).
(E and F) Flow-cytometry analyses revealing the fraction of ES cells expressing aMHC:DsRed-nuc in 0.1%DMSO-treated andCDNG1-treated ES cells. The x axis
is the intensity of Alexa Fluor 488 immunostaining; the y axis is the side scatter area.
(G) Analysis of sarcomeric a-actinin by flow cytometry indicates that CDNG1 treatment enhances cardiomyocyte content 4.36-fold (from 0.83 ± 0.06% to 3.62 ±
0.09%). GCR8-ES cells were treated with 0.1% DMSO and 1 mM CDNG1 from day 4 to day 10 and analyzed at day 12.
(H) Bar chart depicting relative expression folds of bMHC, aMHC,MLC-2a,MLC-2v, and islet in 1 mM CDNG1- and CDNG2-treated ES cells, compared to 0.1%
DMSO-treated controls. bMHC, aMHC, MLC-2a, and MLC-2v were examined at day 12; islet was examined at days 6 and 10. GAPDH was used as internal
controls for normalization. CTL values were arbitrarily set to 1. Graphs (G and H) show mean ± s.d., performed in triplicate; *p < 0.01 compared with control.
See also Movies S1 and S2.
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Discovery of Cardiogenic Small Moleculesin the same region (Figures 6I and 6J). Consistent with EC50
values of Cardionogen-1 and IWR1 using TOPflash reporter
assays in murine ES cells (23 nM versus 7.5 nM, respectively),
these data indicate that Cardionogen reduces Wnt/b-catenin
signaling activity in zebrafish embryos and, further, that IWR1
is a more potent Wnt-pathway antagonist than Cardionogen.
Notably, IWR1 treatment resulted in defects in the anterior-
posterior body development and loss of tail structure posterior
to the yolk extension (Figures 6I, S3A, and S3B). We next exam-
ined whether IWR1 affects heart development. At early stages,
IWR1 treatment caused an increased expression of cardiac
progenitor cell marker nkx2.5 (Figures S3C and S3D) and cardiac
differentiation marker cmlc2, compared to controls (Figures S3E
and S3F). However, at late stages, IWR1-treated embryos dis-
played defects in cardiac chamber formation. Wild-type em-
bryos form two distinct cardiac chambers (atrium and ventricle)Chemistry & Biology 18, 1658–166(Figures S3G and S3I). In contrast, IWR1-treated embryos
develop only one cardiac chamber (Figures S3H and S3J). We
determined the chamber identity using a ventricular marker,
vmhc, and an atrial marker, atrial myosin heavy chain (amhc).
vmhc expression analyses indicated that the single chamber
formed in IWR1-treated embryos possessed ventricular identity
compared to controls (Figure S3K and S3L). amhc expression
analyses revealed atrial myocytes aligned bilaterally in IWR1-
treated embryos, resulting in failure to form the atrium, com-
pared to controls (Figure S3M and S3N).
Cardionogen Reverses Wnt-Induced Cardiac
Phenotypes
Since Cardionogen represses b-catenin/Tcf-mediated tran-
scription in murine cells and zebrafish embryos, we evaluated
whether Cardionogen can rescueWnt-induced cardiac inhibitory8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1663
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Figure 6. Cardionogen Inhibits Wnt3a/b-Catenin-Mediated Transcription
(A) Cardionogen-1 inhibits Wnt3a-induced TOPflash activity in ES cells. CGR8-ES cells were treated with Wnt3a (100 ng/ml)-conditioned media plus CDNG1 or
IWR1 compounds in a series of concentrations. Dose-response curves represent TOPflash activities normalized to cell number (mean ± s.d.; performed in
quadruplicate). The calculated EC50 values for Cardionogen-1 and IWR1 are 23 nM and 7.5 nM, respectively. Graphs were made in Prism 4 (GraphPad Software)
with nonlinear regression fit to a sigmoidal dose-response curve.
(B) Cardionogen does not inhibit Lef/Tcf transcription that is independent of b-catenin activity. CGR8-ES cells were transfected withDNLef-VP16 and treatedwith
1 mM Cardionogen-1 or 1 mM IWR1. Graph represents TOPflash activities (mean ± s.d.; performed in triplicate).
(C) Cardionogen inhibits LRP6-mediated Wnt signaling. CGR8-ES cells were transfected with a constitutively active LRP6ICD and treated with 1 mM
Cardionogen-1, 1 mM IWR1, or 0.1% DMSO (CTL). TOPflash activity is graphed (mean ± s.d; performed in triplicate; *p < 0.01).
(D) Bar chart showing relative expression fold of BMP4-induced Id2 expression (Hua et al., 2006; Nakahiro et al., 2010) in the presence of CDNG1, BMP4,
BMP4+CDNG1, BMP4+DM, compared to its expression in 0.1% DMSO (CTL). Concentrations were 30 ng/ml for Bmp4, 1 mM for CDNG1, and 1 mM for DM. Id2
expression normalized to GAPDH is graphed (mean ± s.d; performed in triplicate; *p < 0.01). CTL values were arbitrarily set to 1.
(E–J) Images taken at 24 hpf (see also Figures S2 and S3). Red arrows indicate GFP expression.
(E and F) Fluorescent optics revealing GFP fluorescence in the midbrain in Tg(TOP:GFP) embryos [outlined area enlarged in (F)].
(G and H) CDNG1 treatment (30 mM; 5–24 hpf) reduces GFP fluorescence in the midbrain of Tg(TOP:GFP) embryos [outlined area enlarged in (H)].
(I and J) IWR1 treatment (30 mM; 5–24 hpf) eliminates GFP fluorescence in the midbrain of Tg(TOP:GFP) embryos [outlined area enlarged in (J)].
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used transgenic zebrafish embryos (Tg[hsp:wnt8-EGFP]), in
which wnt8 fused to EGFP is under the control of a heat-shock
promoter (Ueno et al., 2007). We heat shocked transgenic
embryos to elevate wnt8 expression at the end stage of gastru-
lation (9 hpf), then treated these embryos with Cardionogen-1.
Although cardiomyocyte formation and cmlc2 expression are
normally inhibited in Tg(hsp:wnt8-EGFP) embryos after heat
shock (Figures 7A and 7B), Cardionogen-1 treatment largely
rescued cardiomyocyte deficiency labeled by cmlc2 expression
(Figure 7B and 7C). The same cardiac rescue effects were also
observed by monitoring nkx2.5 expression at the 8-somite
stages (data not shown). Remarkably, the rescue effects per-
sisted through late stages of heart development. Although
wnt8-induced embryos failed to form the atrium and a large part1664 Chemistry & Biology 18, 1658–1668, December 23, 2011 ª2011of the ventricle at 48 hpf (Figures 7D and 7E), Cardionogen-1
treatment completely restored the atrium and ventricle, albeit
with looping defects persisting (Figures 7E and 7F). Notably,
the small eye size induced by wnt8 overexpression was not
rescued in embryos with Cardionogen treatment (Figures
7D–7F), suggesting that Cardionogen may block Wnt sig-
naling in the cardiac mesoderm but not in other tissues. In a
second set of experiments, we examined whether Cardionogen
could inhibit expansion of cardiac cell domains induced by
wnt8 overexpression before gastrulation. Transgenic embryos
(Tg[hsp:wnt8-EGFP]) were heat shocked to inducewnt8 expres-
sion at 3 hpf before gastrulation; this was followed by treatment
with Cardionogen-1. Although cmlc2 expression was expanded
in the lateral plate mesoderm of heat shocked control embryos
(Figures 7G and 7H), Cardionogen-1 treatment reduced theElsevier Ltd All rights reserved
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Figure 7. Cardionogen Rescues Wnt8-Induced Cardiac Phenotypes
(A–C) cmlc2 expression in non-heat-shocked embryos (A), heat-shocked
embryos (B), and CDNG1-treated heat-shocked embryos (C). Of 25 embryos,
23 were rescued.
(D–F) Rescue of heart formation labeled by cmlc2 expression in CDNG1-
treated heat-shocked embryos (F) compared to heat-shocked embryos (E)
and non-heat-shocked embryos (D). Of 26 embryos, 25 were rescued.
(G–I) Inhibition of cardiac expansion labeled by cmlc2 expression in CDNG1-
treated heat-shocked embryos (I), compared to heat-shocked embryos (H)
and non-heat-shocked embryos (G). Of 24 embryos, 21 were inhibited. Heat
shock was administered at 38.5C for 15 min at 3 hpf (H and I) and 9 hpf (B, C,
E, and F). Black arrow, cardiomyocytes; red arrow, ventricle; blue arrow,
atrium.
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these findings demonstrate that Cardionogen reverses Wnt8-
induced heart-specific phenotypes.
DISCUSSION
In this study, we describe an in vivo small-molecule screen in
zebrafish that is capable of identifying chemical modulators of
cardiac development. To our knowledge, we have identified a
family of novel small molecules (named Cardionogen) that
enlarges the size of the embryonic heart by promoting cardio-
myocyte formation. Cardionogen either induces or inhibits the
expansion of cardiac progenitor cells, depending on the timing
and stages of treatment. Importantly, we have linked Cardiono-
gen to the Wnt signaling pathway. Cardionogen inhibits Wnt/
b-catenin signaling activity in murine ES cells (EC50 of 23 nM)
and zebrafish embryos. Cardionogen can rescue Wnt8-induced
cardiomyocyte deficiency and heart-specific phenotypes during
development. These findings demonstrate that a complex but
sensitive development screen targeting organ size can identify
both active small molecules and their target pathways.Chemistry & Biology 18, 1658–166Embryonic heart size primarily reflects cardiac-cell number
and size. However, dysregulation of myocardial patterning and
morphology may also cause alterations in overall heart size. As
such, failure of concentric myocardial growth in heart of glass,
santa, and valentine mutants leads to an enlarged-heart pheno-
type without changing cardiomyocyte number (Mably et al.,
2006; Mably et al., 2003). Therefore, it is critical to determine
whether bioactive small molecules enlarge heart size by modu-
lating cardiomyocyte number, cell size, and/or myocardial
patterning. Notably, only a few zebrafish genetic mutants have
been identified as affecting cardiac cell number, which sug-
gests that certain limitations (e.g., functional redundancy) may
prevent identification of relevant genes and pathways in car-
diomyocyte generation through mutagenesis studies. Small-
molecule screens may overcome these obstacles by identifying
compounds that interact with these important pathways. We
observed that Cardionogen induces murine ES cells to differen-
tiate into cardiomyocytes at 1 mM and 5 mM, but not at 0.1 mM,
indicating that a higher concentration is required to promote
cardiac differentiation in EBs than the concentration (0.1 mM)
used to block Wnt signaling in undifferentiated ES cells. This
might be due to the fact that these two assays are conducted
at two distinct points of ES cell differentiation, each marked
with stage-specific expression of various Wnt ligands (Schulz
et al., 2009). From the TOPflash dose-response analyses,
IWR1 is a more potent Wnt inhibitor than Cardionogen in murine
ES cells. These findings are consistent with activities of Cardio-
nogen and IWR1 in zebrafish Tg(TOP:GFP) embryos, in which
GFP fluorescence in the midbrain is reduced in CDNG1-treated
embryos but eliminated in IWR1-treated embryos. It is noted that
the Cardionogen dose-response curve is steep compared to the
IWR1 dose curve (Figure 6A), suggesting cooperative effects
of Cardionogen in inhibiting TOPflash activity. Multiple Car-
dionogen molecules may bind to one target protein to reduce
TOPflash activity quickly, resulting in a rise in the slope of the
dose-response curve. However, to demonstrate this effect will
require detailed molecular studies of the interaction of Cardiono-
gen with its potential binding proteins in the Wnt pathway.
Wnt signaling is a key regulator of a variety of developmental
processes, including primitive streak formation, mesoderm
and endoderm induction and patterning, anterior-posterior (AP)
axis development, neural differentiation, and heart formation
(Kimelman, 2006; Logan and Nusse, 2004; Moon et al., 2004).
Blocking Wnt signaling in zebrafish development after gastrula-
tion with dickkopf homolog 1 (dkk1) induces cardiac progenitor
cell formation but truncates the posterior axis at late stages
(Ueno et al., 2007). Similarly, we observed that IWR1 treatment
increased the expression of cardiac progenitor cell marker
nkx2.5 but caused AP axis defects and disruption of atrium
formation. Failure to form the atrium might be due to overall em-
bryonic defects (i.e., AP axis abnormality in combination with
other mesoderm defects) in IWR1-treated embryos. Notably,
Cardionogen treatment induces cardiac progenitor cell forma-
tionwithout causing tail truncation and atrium disruption. In addi-
tion, Cardionogen rescued the Wnt8-induced heart defects but
not theWnt8-induced small-eye phenotypes. This demonstrates
the benefits of a whole-organism-based chemical screen. We
believe that the phenotypic differences between zebrafish
treated with IWR1 and those treated with Cardionogen are8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1665
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tion rather than ‘‘off-target’’ effects, although the latter could be
a possibility. Cardionogen might affect only a select population
of Wnt-responding cells in embryos, considering that Cardiono-
gen does not cause overall Wnt-dependent embryonic pheno-
types but affecting Wnt signaling in the heart and the midbrain.
The facts that IWR1 inhibits Wnt signaling in both HEK and ES
cells and can cause typically Wnt-dependent embryonic pheno-
types suggest that IWR1 antagonizes Wnt signaling in broader
cell types and tissues compared to Cardionogen. Importantly,
we have not observed any phenotype independent of Wnt sig-
naling defects in embryos treated with IWR1, suggesting that
the off-target effect is unlikely, or that if there is one, it is minimal.
We wondered whether Cardionogen reduces Tcf/Lef-mediated
luciferase activities in human embryonic kidney (HEK) cells.
Notably, Cardionogen-1 does not inhibit Wnt3a-induced Top-
flash activity in HEK cells, whereas IWR1 does (Figure S2C).
Thus, we propose that Cardionogen selectively reduces Wnt/
b-catenin signaling activity in certain cell types and tissues
(i.e., heart and others) during development. We speculate that
Cardionogen may inhibit tissue (heart)-specific modifiers that
activate Wnt signaling. Alternatively, Cardionogen might inter-
fere with interactions between Wnt pathway components and
tissue (heart)-specific transcriptional factors.
The core components in theWnt signaling pathway have been
clearly defined and studied. However, tissue-specific modifiers
of the pathway remain unknown (Logan and Nusse, 2004;
Moon et al., 2004). Identifying in vivo binding factors of Cardiono-
gen may provide novel insights into the mechanisms related to
tissue-specific modifiers of the Wnt signaling pathway. Recent
studies have established that inhibition of the canonical Wnt
pathway after the germ layer cell formation is necessary to pro-
mote cardiomyocyte differentiation from human cardiovascular
stem cells (Yang et al., 2008). Our findings further support these
human ES cell studies, as treatment of murine ES cells with
Cardionogen after the germ layer cell formation promotes
cardiac differentiation. Thus, evaluating the potential of Cardio-
nogen on human adult and ES cells, along with other known
cardiogenic small molecules (Hao et al., 2008; Sadek et al.,
2008; Wu et al., 2004), is the next logical step in defining thera-
peutic regimens to enhance repopulation of infarcted myocar-
dium and restore function in diseased hearts.
SIGNIFICANCE
There is intense interest in developing chemical probes or
drug leads to influence cardiac differentiation from stem
cells, as well as enhance regenerative capacities in the
heart. Unfortunately, very few cardiogenic small molecules
have been described. The zebrafish has emerged as an
important animal model in multiple steps of drug discovery
process. We have established an exciting approach to dis-
cover small molecules in inducing cardiomyocyte produc-
tion in zebrafish embryos. Three compounds, Cardionogen
1–3, with the same core structure have been discovered.
Characterization of these compounds revealed that the
enlarged heart size in treated embryos is due to the ex-
pansion of cardiac progenitor cell population. Cardiono-
gen induces murine ES cells to differentiate into beating1666 Chemistry & Biology 18, 1658–1668, December 23, 2011 ª2011cardiomyocytes. We show that Cardionogen blocks Wnt/
b-catenin-dependent transcriptional activity in both em-
bryos and ES cells but not in HEK cells, suggesting that
Cardionogen selectively reduces Wnt signaling activity
associated with embryogenesis. Cardionogen treatment
induces cardiogenesis without causing AP axis defects in
zebrafish embryos. However, IWR1 treatment promotes car-
diac differentiation but results in tail truncation and atrium
disruption. Identifying in vivo binding factor of Cardionogen
may provide novel insights into the mechanisms related to
tissue (heart)-specific modifiers of Wnt signaling pathway.
Our findings demonstrate that Cardionogen functions as
a Wnt inhibitor for cardiomyogenesis. This may ultimately
aid in design of therapeutic approaches for cardiac regener-
ation and repair.
EXPERIMENTAL PROCEDURES
Zebrafish Strains and Maintenance
Zebrafish strains used in this study were raised according to standard proce-
dures (Westerfield, 2000). Transgenic lines Tg(cmlc2:EGFP), Tg(cmlc2:DsRed-
nuc), and Tg(hsp:wnt8-EGFP) have been previously described (Burns et al.,
2005; Ueno et al., 2007) ((Mably et al., 2003).
Cardiac Phenotype-Based Small-Molecule Screen
Experimental compounds were obtained from Vanderbilt Institute of Chemical
Biology. Aliquots (1 mL) of the diluted chemical compounds (1 mM) were deliv-
ered into each of the wells using a Labcyte Echo 550. Immediately after aliquot
addition, E3 buffer (69 mL) was delivered into each well. Well12A served as
a negative control (1%DMSO). Embryos were generated by crossing homozy-
gous Tg(cmlc2:EGFP) transgenic fish. Harvested embryos were placed in E3
and incubated at 28.5C. When embryos reached 5 hpf (50% epiboly),
3 embryos were transferred to each well in a 30-mL aliquot of E3 buffer,
bringing the final compound concentration to 10 mM. Plates were incubated
at 28.5C and screened using fluorescent microscopy at 24, 48, and 72 hpf.
Partition Coefficient Analysis
Log P values and molecular weights of bioactive compounds were obtained
from the National Center for Biotechnical Information (http://pubchem.ncbi.
nih.gov)
Cardionogen Synthesis
Synthesis of the Cardionogen series (vuc198 and vuc230) was designed and
conducted by Vanderbilt Chemical Synthesis Core. Compound identities
were confirmed by 1H NMR.
Analyses of Cardiac Cell Number, In Situ Hybridization, and
Immunohistochemistry
The transgenic zebrafish lines Tg(cmlc2:DsRed-nuc) and Tg(cmlc2:EGFP)
were employed to assess changes in cardiomyocyte number and size using
confocal microscopy (Jia et al., 2007; Mably et al., 2003). Whole-mount
in situ hybridizations were carried out as described (Zhong et al., 2001), using
antisense ribonucleotide probes for nkx2.5, cmlc2, vmhc, scl, myoD, and
insulin. Immunofluorescence was performed as described (Jia et al., 2007),
using primary anti-phosphorylated histone H3 antibody (1:100; Santa Cruz
Biotechnology) and secondary antibody Alexa Fluor 555 donkey anti-rabbit
conjugate (1:200; Molecular Probes).
Murine ES Differentiation Assay
Murine CGR8-ES cells were stably transfected with the a-MHC-DsRed-Nuc
plasmid, maintained, and differentiated as described (Hao et al., 2008). Cells
were cultured on gelatin-coated culture plates with Glasgow Minimum Essen-
tial Medium (GMEM; Sigma) containing 10% heat-inactivated FBS, 20 mM
L-Glutamine, 50 mM b-Mercaptoethanol, and 100 units/ml Leukemia Inhibitory
Factor (ESGRO-Chemicon). CGR8-ES cells were differentiated in Iscove’sElsevier Ltd All rights reserved
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inactivated FBS, 16 mM L-Glutamine, nonessential amino acids, and 80 mM
b-Mercaptoethanol. EBs were initiated (day 0) and grown in hanging drops
for two days. Each EB initially consisted of 500 cells in 20 ml of IMDM dif-
ferentiation medium. Formed EBs were washed down into an uncoated Petri
dish and suspended in IMDM differentiation medium for two more days. On
day 4, EBs were transferred to gelatin-coated plates, allowed to attach, and
incubated in differentiation medium until the analyses on day 12. The medium
was replaced every 48 hr, and differentiating cell cultures weremicroscopically
examined for the presence of contractile cardiomyocytes marked by red fluo-
rescence. Cells were harvested at day 12 and RNAs were isolated using
RNeasy kit (QIAGEN) for real-time RT-PCR (see Supplemental Experimental
Procedure).
Fluorescence-Activated Cell Sorting
EBs created with CGR8-ES cell line were washed in 1X PBS and dissociated
with collagenase (20mg/ml) in 1X PBS. These cells were centrifuged for
3.5 min at 3500 rpm. Supernatant was removed and cells were washed with
fluorescence-activated cell sorting buffer (1X PBS and 5% Fetal bovine
serum). Washed cells were fixed in 2% PFA/PBS for 10 min, and probed using
the first a-Actinin monoclonal antibody (Sigma; 1:2,000 dilution), then the
secondary antibody goat anti-mouse IgG Alexa Fluor 488 (Invitrogen; 1:200
dilution). Cells were sorted on LSR-II (BD Biosciences) and analyzed using
FACS Diva v6.1.3 software.
Reporter Assay
Murine CGR8-ES cells were transfected with constructs of pTOPflash reporter
(Upstate Biotechnology Inc., now Millipore), RBP-Jk reporter, or SRF/MAPK
reporter (SABiosciences), using Lipofectamine 2000 transfection reagent
(Invitrogen). These transfected cells were grown in feeder-free conditions as
monolayers in GMEM medium supplemented with 10% FBS, 100 units/ml
LIF, 2 mM L-glutamine, and 50 mM b-mercaptoethanol in a humidified 5%
CO2 atmosphere at 37
C, as described (Meyer et al., 2000). HEK293 cells
were maintained in DMEM, 10% FBS, and antibiotics. Cells were then lysed
with 1X Passive Lysis Buffer (Promega). Luciferase activity was measured by
Steady-Glo Luciferase Assay (Promega) on a Monolight 2010 Luminometer
(Analytical Luminescence Laboratory) and normalized to viable cell number
using the CellTiter-Glo Assay (Promega). Graphs were made in Prism 4
(GraphPad Software) with nonlinear regression fit to a sigmoidal dose-
response curve.
Wnt8-Induced Cardiac Phenotype Assays
Tg(hsp:wnt8-EGFP) fish were out-crossed to the wild-type AB line. Progeny
embryos were all heterozygous for the transgene. Embryos at 3 hpf or 9 hpf
were placed in 15-ml Falcon tubes with E3 buffer. The tubes were then
submerged in a 38.5C water bath for 15 min for heat shock, while non-
heat-shock control embryos were maintained at 25C. After heat shock,
embryos were washed with E3 at room temperature. Heat-shocked embryos
were either treated with CDNG1 (90 mM) or returned to E3 buffer as controls. All
embryos were incubated at 25C until fixation at 17 hpf or 48 hpf for in situ
hybridization analyses.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two movies, and Supple-
mental Experimental Procedures, and can be found with this article online at
doi:10.1016/j.chembiol.2011.09.015.
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